Kris Ballantyne, Partners Life chief marketing officer, says after reviewing and analysing customer and product data built up during its 11 years in business, the company had been able to identify pockets of risk where customers were being under-charged in comparison to the number of claims they were generating.
“Effectively, these customers were being subsidised by other customers,” Ballantyne says. But the firm now has the data and tools to “reshape” its pricing and set premiums at a level that’s fairer for all customers. “This is a reshaping,” he says. “It’s not a price increase across the board.”
Premium will now depend upon customer profiles and for some, the increase will be more “pertinent” than for others. For example, 20% of policies have seen increases of less than 10% and only 10% of policies faced the steepest premium rise (20%).
“But even in the most extreme scenarios, we’re not talking about the difference between a Toyota and a Maserati. We’re talking about a relatively close gap. It means that Partners Life is sometimes at the top of the market but not by an insurmountable percentage.”
Being able to compile and use its own data has made all the difference, rather than having to rely on actuarial data from reinsurers and other global sources which doesn’t necessarily relate to specific Partners Life products or its demographic mix.
Ballantyne says both regulators have been asking insurers to address cross-subsidisation. And back in December 2021, when the premium increases were first announced, Partners Life said cross-subsidisation of high-claiming pockets of customers was “inherently unfair”.
As an example of the anomalies it can throw up, a company video made late last year for advisers referenced a chart showing the ratio of actual to expected female trauma claims.
Anton Gardiner, then Partners Life chief actuary, said claims from some age groups within this female cohort were much higher than expected – for example, women aged 40-49, where 84% of trauma claims were for cancer and of these, 62% were for breast cancer.
“In fact, breast cancer accounted for 52% of all trauma claims in that age group,” Gardiner said. “We [were] simply not charging enough for the number of claims were [were] seeing.”
Now working as chief of product and pricing, Gardiner says claims are the biggest component of the overall premium cost – between 50% and 60%, and even higher for medical cover.
The next biggest component is commission, both initial and renewal; Partners Life pays one of the highest renewal commissions in the market (10%). The final (and much smaller) components of the premium are operating expenses and profit, with profit being the smallest, Gardiner says.
Claims is the only area where costs are not relatively stable. “If claims are increasing and the other [components] remain the same, the profitability of us as an insurer gets squeezed. That’s not good for us or for the industry.”
Nevertheless, says chief actuary Kate Dron, the premium increases have not been simply about increasing profits. In fact, she says, it’s the opposite.
“We’re looking at how we can maintain profitability but also [ensuring] that we’re charging a fair price to our customers. When claims increase, we’ve got to look at adjusting our premiums to reflect that and how we can do it equitably across our customers. Increasing profitability is not an outcome of these price increases.”
Gardiner says while Partners Life decided to tackle the problem head-on, and accepted that for a time this might make it less competitive, other insurers will eventually have to make the same sort of adjustment.
Dron describes it as a “claims spiral” when others start attracting the sort of customers that Partners Life has identified as higher risk.
“It won’t necessarily happen to us because we no longer have those pockets or if we do, we’ve priced for it appropriately,” she says. “It’s taken us 11 years to get here but we’re very comfortable with where we’ve landed – that the shape of our pricing curve is now very reflective of where we expect our business to be [in the future].”
She concedes that external factors outside the control of Partners Life – such as new medical innovations or diagnostics – could impact future pricing but says such things will affect the whole industry, not just Partners Life. “But in terms of our own portfolio and treating our customers fairly, we’re comfortable with that.”
Pricing will continue to be reviewed every year but, barring “externalities”, there should be no need for big adjustments, Dron says.